menu
close_24px

Support for Patients With Reduced Blood Flow From Advanced PAD, CLTI, and Ischemia

Support for complex PAD and CLTI cases where reduced blood flow has led to non‑healing wounds or progressive ischemia, alongside investigational evaluation programs for vascular dementia, chronic pain, cardiovascular ischemia, and longevity. 

Support for Patients With Reduced Blood Flow From Advanced PAD, CLTI, and Ischemia

Support for complex PAD and CLTI cases where reduced blood flow has led to non‑healing wounds or progressive ischemia, alongside investigational evaluation programs for vascular dementia, chronic pain, cardiovascular ischemia, and longevity. 

When to Consider a Clinical Evaluation Pathway

Physicians managing advanced PAD and CLTI routinely encounter patients whose reduced blood flow continues to worsen despite appropriate revascularization and standard wound care. These cases often require a deeper review to determine whether the patient may be appropriate for investigational evaluation programs focused on ischemia‑related conditions.
 
Patients may benefit from a structured clinical assessment when you observe:
 
Non‑healing ischemic wounds that persist despite guideline‑directed wound care and prior interventions
Progressive ischemia or worsening perfusion findings after revascularization
Rest pain or ischemic pain that remains unresponsive to conventional management
Limited or no remaining revascularization options, including cases where further intervention is not feasible or not expected to improve reduced blood flow
Persistent reduced blood flow documented through imaging, hemodynamic testing, or clinical examination
Limb‑threatening ischemia requiring multidisciplinary review to determine next steps
Patients seeking investigational evaluation after exhausting standard care pathways for ischemia‑related conditions
 
These scenarios may warrant consideration of investigational evaluation programs that include advanced ischemia as well as related research areas such as vascular dementia, chronic pain, cardiovascular ischemia, and longevity-focused studies.

When to Consider a Clinical Evaluation Pathway

Physicians managing advanced PAD and CLTI routinely encounter patients whose reduced blood flow continues to worsen despite appropriate revascularization and standard wound care. These cases often require a deeper review to determine whether the patient may be appropriate for investigational evaluation programs focused on ischemia‑related conditions.
 
Patients may benefit from a structured clinical assessment when you observe:
 
Non‑healing ischemic wounds that persist despite guideline‑directed wound care and prior interventions
Progressive ischemia or worsening perfusion findings after revascularization
Rest pain or ischemic pain that remains unresponsive to conventional management
Limited or no remaining revascularization options, including cases where further intervention is not feasible or not expected to improve reduced blood flow
Persistent reduced blood flow documented through imaging, hemodynamic testing, or clinical examination
Limb‑threatening ischemia requiring multidisciplinary review to determine next steps
Patients seeking investigational evaluation after exhausting standard care pathways for ischemia‑related conditions
 
These scenarios may warrant consideration of investigational evaluation programs that include advanced ischemia as well as related research areas such as vascular dementia, chronic pain, cardiovascular ischemia, and longevity-focused studies.

Scientific Rationale for Investigational Evaluation

Advanced PAD, CLTI, and other ischemia‑related conditions share a core problem: reduced blood flow that disrupts tissue repair, microvascular function, and cellular signaling. When revascularization is no longer feasible or has failed to improve perfusion, patients often experience non‑healing ischemic wounds, progressive ischemia, rest pain, and limb‑threatening complications. These patterns reflect deeper biological issues such as impaired angiogenesis, microvascular decline, chronic inflammation, and reduced regenerative capacity.
 
Similar mechanisms appear in vascular dementia, chronic pain, cardiovascular ischemia, and longevity‑focused research, where reduced perfusion and cellular exhaustion contribute to functional decline. Investigational evaluation programs explore whether patients with these complex conditions may be appropriate for research focused on microcirculation, angiogenic signaling, inflammatory modulation, and regenerative biology within structured clinical frameworks.

Scientific Rationale for Investigational Evaluation

Advanced PAD, CLTI, and other ischemia‑related conditions share a core problem: reduced blood flow that disrupts tissue repair, microvascular function, and cellular signaling. When revascularization is no longer feasible or has failed to improve perfusion, patients often experience non‑healing ischemic wounds, progressive ischemia, rest pain, and limb‑threatening complications. These patterns reflect deeper biological issues such as impaired angiogenesis, microvascular decline, chronic inflammation, and reduced regenerative capacity.
 
Similar mechanisms appear in vascular dementia, chronic pain, cardiovascular ischemia, and longevity‑focused research, where reduced perfusion and cellular exhaustion contribute to functional decline. Investigational evaluation programs explore whether patients with these complex conditions may be appropriate for research focused on microcirculation, angiogenic signaling, inflammatory modulation, and regenerative biology within structured clinical frameworks.

ACP-01 Clinical Programs and Indications

ACP‑01 has been evaluated or is currently under investigation across multiple vascular and ischemia‑related conditions where reduced blood flow, microvascular decline, or impaired tissue repair play a central role. Research programs have included advanced PAD and CLTI, as well as broader ischemic and neurovascular conditions such as vascular dementia, chronic pain, cardiovascular ischemia, and longevity‑focused studies.

These programs are designed to assess safety, biological activity, and potential mechanisms of action in patients who have exhausted standard care pathways. The chart below outlines ongoing clinical studies across these investigational areas.

Clinical Trials Image

These programs represent structured clinical development efforts targeting limb ischemia, myocardial ischemia, and vascular-related cognitive impairment. ACP-01 remains investigational in all indications.

Mechanism of Action: Autologous Angiogenic Cell Therapy

Mechanism of Action: Autologous Angiogenic Cell Therapy

ACP-01 comprises autologous angiogenic precursor cells derived from a patient’s peripheral blood. Cells are isolated and prepared under controlled laboratory protocols prior to re-administration.

The biological rationale includes:

Support of angiogenesis in ischemic tissue
Modulation of endothelial repair pathways
Potential enhancement of microvascular perfusion
Autologous compatibility minimizing immunologic mismatch

Additional scientific background is available on the ACP-01 therapy page. 

ACP-01 is investigational and continues to be evaluated in clinical research settings.

Why Physicians Choose Hemostemix for Complex Ischemia Cases

Hemostemix supports physicians managing advanced PAD, CLTI, and other ischemia‑related conditions by offering a structured, research‑aligned evaluation pathway for patients with persistent reduced blood flow and limited remaining options. The focus is on cases involving non‑healing ischemic wounds, progressive ischemia, or rest pain after revascularization.
 
Physicians value the multidisciplinary review process, the emphasis on ischemia’s underlying biology, and the availability of investigational programs that extend beyond limb ischemia into vascular dementia, chronic pain, cardiovascular ischemia, and longevity research. Communication remains clear and clinical, ensuring referring physicians stay informed throughout the evaluation process.

Why Physicians Choose Hemostemix for Complex Ischemia Cases

Hemostemix supports physicians managing advanced PAD, CLTI, and other ischemia‑related conditions by offering a structured, research‑aligned evaluation pathway for patients with persistent reduced blood flow and limited remaining options. The focus is on cases involving non‑healing ischemic wounds, progressive ischemia, or rest pain after revascularization.
 
Physicians value the multidisciplinary review process, the emphasis on ischemia’s underlying biology, and the availability of investigational programs that extend beyond limb ischemia into vascular dementia, chronic pain, cardiovascular ischemia, and longevity research. Communication remains clear and clinical, ensuring referring physicians stay informed throughout the evaluation process.

 Phase II Clinical Evidence in Chronic Limb Threatening Ischemia 

Prospective Phase II structured clinical evaluation in patients with advanced CLTI who were not candidates for further revascularization.

Patients diagnosed with advanced peripheral arterial disease progressing to chronic limb threatening ischemia.

Ulcer size reduction
Amputation-free survival
Mortality tracking
Safety outcomes

Published data have reported reductions in ulcer size at defined follow-up intervals compared to baseline measurements. Lower combined amputation or death rates were observed in treated cohorts relative to control groups in reported analyses. Follow-up extended through defined timepoints, with no treatment-related complications reported at one year in published findings.

Detailed study information and references are available in the Clinical Research section. 

Compliance note: We state “published data have reported” and “observed” rather than stating outcomes as guarantees.

Clinical Research in Ischemic Cardiomyopathy and Heart Failure

ACP-01 has been evaluated in patients with ischemic and dilated cardiomyopathy characterized by reduced ejection fraction and symptomatic heart failure.

Structured evaluations have included assessment of:

Left ventricular ejection fraction
Functional capacity measures
Symptom burden
Safety monitoring

Published and retrospective analyses have described changes in cardiac function parameters in defined patient subsets. These findings remain investigational and require further validation through controlled clinical trials.

For additional research summaries:

Again, no implication of standard-of-care efficacy.

 Vascular Dementia Clinical Trial Program

Vascular dementia is associated with impaired cerebral perfusion and microvascular ischemic injury.

ACP-01 investigational research in vascular dementia is grounded in its angiogenic and microvascular support rationale. Ongoing and planned studies are designed to evaluate safety and defined cognitive endpoints in selected patient populations.

For patient-facing overview of vascular dementia research:

All vascular dementia investigations remain investigational.

Study Design, Endpoints and Safety Monitoring

Across evaluated programs, ACP-01 clinical research has incorporated:

Prospective Phase II evaluations
Defined inclusion and exclusion criteria
Intent-to-treat analytical frameworks
Structured safety monitoring protocols
Longitudinal follow-up assessments

Real-world evidence generation under jurisdictional oversight may complement structured clinical research where applicable.

Further randomized and controlled trials are required to determine comparative efficacy and long-term outcomes.

Regulatory Status and Investigational Use

ACP-01 is an investigational therapy and is not approved by the U.S. Food and Drug Administration for general use. Regulatory status varies by jurisdiction.

In select jurisdictions, autologous cellular therapies may be offered within defined regulatory frameworks and under appropriate oversight. Physicians should review applicable local regulations and institutional policies before considering investigational approaches.

Physician Inquiry and Research Collaboration

Physicians seeking additional clinical data, study protocols, peer-reviewed publications, or collaboration discussions may submit a professional inquiry.

Disclaimer

IMPORTANT NOTICE
ACP-01 is an investigational therapy and has not been approved by the U.S. Food and Drug Administration. Information provided on this website is for educational purposes only and does not constitute medical advice. Nothing on this site is intended to promote or market an unapproved therapy. Patients should consult a qualified healthcare professional regarding diagnosis and treatment decisions.
 
FLORIDA NOTICE
This notice is provided in accordance with Florida law. One or more physicians referenced may perform stem cell therapies that have not been approved by the United States Food and Drug Administration. Patients are encouraged to consult with their primary care provider before undergoing any stem cell therapy.